Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus

Cited by (452)

Items 101–200 of 452

1. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta‐analysis
   Zhen Zhang, Yang Cao, Yujia Tao, Meng E, Jiahao Tang, Yongcui Liu, Fangping Li · 2019 · Diabetes Research and Clinical Practice
2. Osteoporosis and Fracture Risk in Patients with Type 2 Diabetes Mellitus
   Cătălina Poiană · 2019 · Acta Endocrinologica (Bucharest)
3. Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
   Xin Wang, Fengyi Zhang, Yufeng Zhang, Jia‐Yi Zhang, Yingli Sheng, Wenbo Wang, Yujie Li · 2023 · Osteoporosis International
4. Treatment of type 2 diabetes mellitus in elderly patients
   Ricardo Gómez‐Huelgas, F. Gómez Peralta, Leocadio Rodríguez‐Mañas, Francesç Formiga, Manel Puig‐Domingo, José Javier Mediavilla Bravo, C. Miranda, Javier Ena · 2018 · Revista Clínica Española (English Edition)
5. Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations
   Stergios A. Pοlyzos, Athanasios D. Anastasilakis, Zoe A. Efstathiadou, Maria P. Yavropoulou, Polyzois Makras · 2021 · Maturitas
6. Canagliflozin review – safety and efficacy profile in patients with T2DM
   Haroon Jakher, Tara I. Chang, Marilyn J. Tan, Kenneth W. Mahaffey · 2019 · Diabetes Metabolic Syndrome and Obesity
7. La paradoja diabética: densidad mineral ósea y fractura en la diabetes tipo 2
   Sonsoles Botella Martínez, Nerea Varo, Javier Escalada, Amparo Calleja Canelas · 2016 · Endocrinología y Nutrición
8. Current Antidiabetic Drugs
   Hossain, Md. Akil, Pervin, Rokeya · 2018 · Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome
9. Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies
   Khemayanto Hidayat, Qi Fang, Bimin Shi, Li‐Qiang Qin · 2021 · Osteoporosis International
10. Diabetes Drug Effects on the Skeleton
    Manju Chandran · 2016 · Calcified Tissue International
11. SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus
    Jayant Dey · 2017 · Postgraduate Medicine
12. Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD)
    Raymond Camille Vanholder, Steven Van Laecke, Griet Glorieux, Francis Verbeke, Esmeralda Castillo-Rodríguez, Alberto Ortíz · 2018 · Toxins
13. Risks vs Benefits for SGLT2 Inhibitor Medications.
    Shanti Pittampalli, Satya Upadyayula, Hema Madhuri Mekala, Steven Lippmann · 2018 · Europe PMC (PubMed Central)
14. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study
    Adam Goldman, Boris Fishman, Gilad Twig, Emanuel Raschi, Tali Cukierman‐Yaffe, Yonatan Moshkovits, Alon Pomerantz, Ilan Ben‐Zvi, Rachel S. Dankner, Elad Maor · 2023 · Cardiovascular Diabetology
15. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
    Ioana-Cristina Bica, Roxana Adriana Stoica, Teodor Salmen, Andrej Janež, Špela Volčanšek, Djordje S. Popovic, Emir M. Muzurović, Manfredi Rizzo, Anca Pantea Stoian · 2023 · Medicina
16. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials
    Md Azharuddin, Mohammad Adil, Pinaki Ghosh, Manju Sharma · 2018 · Diabetes Research and Clinical Practice
17. Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease
    Tamara Y. Milder, SOPHIE LENA STOCKER, Richard Osborne Day, Jerry Richard Greenfield · 2020 · Drug Safety
18. Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes
    Trujillo, Jennifer M., Nuffer, Wesley A. · 2017 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
19. Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
    Kamlesh Khunti, Serge A Jabbour, Xavier Cos, Sunder Raj D. Mudaliar, Christian W. Mende, Marc P. Bonaca, Paola Fioretto · 2022 · Diabetes Obesity and Metabolism
20. Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
    Lawrence Blonde, Susana Dipp, Daniel Cadena · 2018 · Advances in Therapy
21. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
    Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria‐Inti Metzendorf, Bernd Richter, Bianca Hemmingsen · 2019 · Cochrane Database of Systematic Reviews
22. Fracture Patterns in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review of Recent Literature
    Veerle van Hulten, Nicklas H. Rasmussen, Johanna H. M. Driessen, Andrea Michelle Burden, Annika Vestergaard Kvist, Joop P. van den Bergh · 2021 · Current Osteoporosis Reports
23. Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
    Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, Robert M. Gifford, S. Moser, Sarah H. Wild, Rebecca M. Reynolds, David John Webb, Helen Martina Colhoun · 2021 · Diabetes Therapy
24. Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
    Ricardo Gómez‐Huelgas, F. Gómez Peralta, Leocadio Rodríguez‐Mañas, Francesç Formiga, Manel Puig‐Domingo, José Javier Mediavilla Bravo, C. Miranda, Javier Ena · 2018 · Revista Española de Geriatría y Gerontología
25. Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018
    Fernando Gómez Peralta, Javier Escalada, Edelmiro Luis Menéndez Torre, Manel Mata‐Cases, Juan Carlos Ferrer García, Patxi Ezkurra Loiola, Luis Ávila Lachica, José Antonio Fornos Pérez, Sara Artola Menéndez, Fernando Álvarez Guisasola et al. · 2018 · Endocrinología Diabetes y Nutrición
26. Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
    Sanbao Chai, Fengqi Liu, Zhirong Yang, Shuqing Yu, Zuoxiang Liu, Qingqing Yang, Feng Sun · 2022 · Frontiers in Pharmacology
27. Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
    John P.H. Wilding, Surya Panicker Rajeev, Ralph Anthony DeFronzo · 2016 · Diabetes Care
28. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
    Thomas Blevins, Azeez Farooki · 2016 · Postgraduate Medicine
29. Initiation of dapagliflozin and treatment‐emergent fractures
    Konstantinos A. Toulis, John Paul Bilezikian, G. Neil Thomas, Wasim Hanif, Kalliopi Kotsa, Rasiah Thayakaran, Deepiksana Keerthy, Abd A. Tahrani, Krishnarajah Nirantharakumar · 2017 · Diabetes Obesity and Metabolism
30. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
    Elizabeth Mary Lamos, Maka S. Hedrington, Stephen N. Davis · 2019 · Expert Opinion on Drug Safety
31. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Agostino Consoli, Gloria Formoso, MARIA POMPEA ANTONIA BALDASSARRE, Fabrizio Febo · 2018 · Expert Opinion on Drug Safety
32. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
    Janet B. McGill, Savitha Subramanian · 2019 · The American Journal of Medicine
33. Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
    Harindra Rajasekeran, David Z.I. Cherney, Julie A. Lovshin · 2017 · Current Opinion in Nephrology & Hypertension
34. Fracture risk associated with common medications used in treating type 2 diabetes mellitus
    Daniel Wolverton, Melissa M. Blair · 2017 · American Journal of Health-System Pharmacy
35. Complex interplay among adiposity, insulin resistance and bone health
    Chun‐Ming Ma, Katherine Thuy Trang Tonks, Dorit Samocha‐Bonet, Jerry Richard Greenfield · 2018 · Clinical Obesity
36. Therapeutic strategies for type 2 diabetes mellitus in women after menopause
    Stavroula Α. Paschou, Ljiljana Marina, Eleftherios D Spartalis, Panagiotis G. Anagnostis, Andreas P. Alexandrou, Dimitrios G. Goulis, Irene V. Lambrinoudaki · 2019 · Maturitas
37. Review article: effects of type 2 diabetes therapies on bone metabolism
    André Gustavo Daher Vianna, Claudia P. Sanches, Fellype Carvalho Barreto · 2017 · Diabetology & Metabolic Syndrome
38. Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects
    Joaquim Custódio da Silva, Jarbas de Sá Roriz Filho, Catarina Addobbati Jordão Cavalcanti, Amanda Martins, João Eduardo Nunes Salles · 2020 · Drugs & Aging
39. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance
    Neil Tanday, Nigel Irwin, Peter R. Flatt, R. Charlotte Moffett · 2020 · Biochemical Pharmacology
40. Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: challenges of complex models
    Sabrina Ehnert, Helen Rinderknecht, Romina H. Aspera-Werz, Victor Häussling, Andreas Klaus Nussler · 2020 · Archives of Toxicology
41. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
    Paresh Dandona, Ajay Chaudhuri · 2017 · International Journal of Clinical Practice
42. Sodium‐glucose co‐transporter‐2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case–control study
    Niklas Schmedt, Frank Andersohn, Jochen Walker, Edeltraut Garbe · 2018 · Diabetes Obesity and Metabolism
43. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
    Andrea Cowan, Nivethika Jeyakumar, Yuguang Kang, Stephanie N. Dixon, Amit X. Garg, Kyla L. Naylor, Matthew A. Weir, Kristin K. Clemens · 2022 · Clinical Journal of the American Society of Nephrology
44. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
    Curt J. Carlson, Marile L Santamarina · 2016 · Expert Opinion on Drug Safety
45. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
    Jaime A. Davidson, Lance Alan Sloan · 2016 · Advances in Therapy
46. The diabetic paradox: Bone mineral density and fracture in type 2 diabetes
    Sonsoles Botella Martínez, Nerea Varo, Javier Escalada San Martín, Amparo Calleja Canelas · 2016 · Endocrinología y Nutrición (English Edition)
47. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
    Joanna Sophia J. Vinke, Hiddo J.L. Heerspink, Martin H. de Borst · 2019 · Current Opinion in Nephrology & Hypertension
48. When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
    Angelo Avogaro, Elías Delgado, Ildiko Lingvay · 2018 · Diabetes/Metabolism Research and Reviews
49. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis
    Rong Qiu, Dainius A. Balis, John Xie, Michael J. Davies, Mehul G. Desai, Gary E. Meininger · 2016 · Current Medical Research and Opinion
50. Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review
    Lingli Xie, Xia Wenfang · 2022 · Life Sciences
51. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern‐En Chiang, Kwo-Chang Ueng, Ting‐Hsing Chao, Tsung‐Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih‐Hsien Sung, Hung‐I Yeh, Yi‐Heng Li, Ping‐Yen Liu et al. · 2020 · Journal of the Chinese Medical Association
52. Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study
    Matthias Rau, Kirsten Thiele, Niels‐Ulrik Korbinian Hartmann, Julia Möllmann, Stephanie Wied, Mathias Hohl, Nikolaus Marx, Michael Lehrke · 2022 · Bone Reports
53. SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure
    Rahul Gupta, Theresa Maitz, David Egeler, Anila Mehta, Mark S. Nyaeme, Adrija Hajra, Akshay Goel, Jayakumar Sreenivasan, Neelkumar Patel, Wilbert S. Aronow · 2022 · Trends in Cardiovascular Medicine
54. Adverse bone effects of medications used to treat non-skeletal disorders
    Nelson B. Watts · 2017 · Osteoporosis International
55. Oleanolic Acid Enhances Mesenchymal Stromal Cell Osteogenic Potential by Inhibition of Notch Signaling
    Bing Shu, Yongjian Zhao, Yongjun Wang, Guangxi Wang, Xifu Shang, Michael Britt, Margaret L. Olmedo, Marjorie R. Chelly, Massimo Morandi, Richard Shane Barton et al. · 2017 · Scientific Reports
56. Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
    Awadhesh Kumar Singh, AG Unnikrishnan, Abdul Hamid Zargar, Ajay Kumar, Ashok Kumar Das, Banshi Saboo, Binayak Sinha, Kalyan Kumar Gangopadhyay, Pradeep Talwalkar, Samit Ghosal et al. · 2019 · Diabetes Therapy
57. Effect of antidiabetic treatment on bone.
    P. Jackuliak, Martin Kužma, Juraj Payer · 2019 · Physiological Research
58. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
    André Jacques Scheen · 2020 · Expert Opinion on Drug Safety
59. Dapagliflozin and Liraglutide Therapies Rapidly Enhanced Bone Material Properties and Matrix Biomechanics at Bone Formation Site in a Type 2 Diabetic Mouse Model
    Aleksandra Mieczkowska, Paul Millar, Daniel Chappard, Victor A. Gault, Guillaume Mabilleau · 2020 · Calcified Tissue International
60. Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
    Laleh Razavi-Nematollahi, Faramarz Ismail‐Beigi · 2019 · Current Diabetes Reports
61. Bexagliflozin for type 2 diabetes: an overview of the data
    Omar Azzam, Revathy Carnagarin, Leslie Marisol Lugo‐Gavidia, Janis Marc Nolde, Vance Bruce Matthews, Markus Peter Schlaich · 2021 · Expert Opinion on Pharmacotherapy
62. Impact of Body Weight Loss From Maximum Weight on Fragility Bone Fractures in Japanese Patients With Type 2 Diabetes: The Fukuoka Diabetes Registry
    Yuji Komorita, Masanori Iwase, Hiroki Fujii, Toshiaki Ohkuma, Hitoshi Ide, Tamaki Jodai, Akiko Sumi, Masahito Yoshinari, Udai Nakamura, Dongchon Kang et al. · 2018 · Diabetes Care
63. The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
    Marie Ito, Tetsuhiro Tanaka · 2018 · Internal Medicine
64. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
    Riobaldo M.R. Cintra, Filipe A. Moura, Luiz Sérgio Fernandes de Carvalho, Joaquim Barreto, Marcos Antônio Tambascia, Roberto Pecoits‐Filho, Andrei Carvalho Sposito · 2019 · Revista da Associação Médica Brasileira
65. Sodium‐glucose co‐transporter 2 inhibitors and the risk of fractures: A propensity score‐matched cohort study
    Sruthi Adimadhyam, Todd A. Lee, Gregory Sampang Calip, Daphne E. Smith Marsh, Brian Thomas Layden, Glen T. Schumock · 2019 · Pharmacoepidemiology and Drug Safety
66. Low Bone Turnover Markers in Young and Middle-Aged Male Patients with Type 2 Diabetes Mellitus
    X. X. Liu, Lijuan Jiang, Q. Liu, J. Zhang, Wenyan Niu, J. Liu, Qunjuan Zhang · 2020 · Journal of Diabetes Research
67. Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
    Curtis L. Triplitt, Susan A. Cornell · 2015 · Clinical Medicine Insights Endocrinology and Diabetes
68. Research progress of diabetic osteoporosis: a comprehensive review
    Xun Ma, Xiaoqian Zhang · 2025 · Frontiers in Endocrinology
69. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
    Matthew Jay Budoff, John P.H. Wilding · 2017 · International Journal of Clinical Practice
70. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits
    Kristen M. Jackson, Kendall F. Moseley · 2020 · Current Osteoporosis Reports
71. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
    Zheer Kejlberg Al-Mashhadi, Rikke Viggers, Jakob Starup‐Linde, Peter Vestergaard, Søren Gregersen · 2022 · Frontiers in Endocrinology
72. Acid-base and electrolyte disorders associated with the use of antidiabetic drugs
    Theodosios D. Filippatos, Eleftheria Tzavella, Christos V. Rizos, Moses Elisaf, George L. Liamis · 2017 · Expert Opinion on Drug Safety
73. Sodium glucose cotransporters inhibitors in type 1 diabetes
    Sergio Dellepiane, Moufida Ben Nasr, Emma Assi, Vera Usuelli, Teresa Letizia, Francesca D’Addio, Gianvincenzo Zuccotti, Paolo Fiorina · 2018 · Pharmacological Research
74. Can Glucose-Lowering Medications Improve Outcomes in Non-Diabetic Heart Failure Patients? A Bayesian Network Meta-Analysis
    Trevor James Jun‐Ming Yeong, Aaron Shengting Mai, Oliver Zi-Hern Lim, Cheng Han Ng, Yip Han Chin, Phoebe Wen Lin Tay, Chaoxing Lin, Mark Dhinesh Muthiah, Chin Meng Khoo, Mayank Dalakoti et al. · 2022 · ESC Heart Failure
75. Diabetes and bone
    Iana Mizumukai de Araújo, Mariana Lima Mascarenhas Moreira, Francisco José Albuquerque de Paula · 2022 · Archives of Endocrinology and Metabolism
76. Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice
    Peiyang Song, Tianyi Chen, Shunli Rui, Xiaodong Duan, Bo Deng, David G. Armstrong, Yu Ma, Wuquan Deng · 2022 · Frontiers in Endocrinology
77. Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes
    Christian W. Mende · 2016 · Current Medical Research and Opinion
78. Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial
    André Gustavo Daher Vianna, Claudio Silva de Lacerda, Luciana Muniz Pechmann, Michelle Garcia Polesel, Emerson Cestari Marino, Victória Zeghbi Cochenski Borba, Fellype de Carvalho Barreto · 2017 · Diabetology & Metabolic Syndrome
79. Bone Fragility in Diabetes and its Management: A Narrative Review
    David Suphadetch Leungsuwan, Manju Chandran · 2024 · Drugs
80. The Effect of Type 2 Diabetes on Bone Biomechanics
    Lamya Karim, Taraneh Rezaee, Rachana Vaidya · 2019 · Current Osteoporosis Reports
81. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
    Shrita M. Patel, Anne Hickman, Robert C. Frederich, SUSAN L. JOHNSON, Susan B. Huyck, James P. Mancuso, Ira Gantz, Steven G. Terra · 2020 · Diabetes Therapy
82. Geroprotector drugs and exercise: friends or foes on healthy longevity?
    Christian J. Elliehausen, Rozalyn M. Anderson, Gary M. Diffee, Timothy W. Rhoads, Dudley W. Lamming, Troy Alan Hornberger, Adam R. Konopka · 2023 · BMC Biology
83. Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
    Anna Solini · 2016 · Acta Diabetologica
84. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health
    Andrea Egger, MARIUS E. KRAENZLIN, Christian Meier · 2016 · Current Osteoporosis Reports
85. The effects of diabetes therapy on bone: A clinical perspective
    Karim G. Kheniser, Carmen M. Polanco Santos, Sangeeta Rao Kashyap · 2018 · Journal of Diabetes and its Complications
86. Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus
    Abdul‐Rahman Azizogli, Michael Vitti, Richa Mishra, Laura Osorno, Corey Heffernan, Vivek Kumar · 2023 · Advanced Therapeutics
87. Bone Health in Patients With Type 2 Diabetes
    Patrice M. Forner, Angela Sheu · 2024 · Journal of the Endocrine Society
88. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
    Qian, B-B., Chen, Q., Li, L., Yan, C-F. · 2020 · Osteoporosis International
89. 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern‐En Chiang, Shih-Yi Lin, Tsung‐Hsien Lin, Tzung‐Dau Wang, Hung‐I Yeh, Jung‐Fu Chen, Chia‐Ti Tsai, Yi-Jen Hung, Yi‐Heng Li, Ping‐Yen Liu et al. · 2018 · Journal of the Chinese Medical Association
90. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Yake Lou, Ying Yu, Junchao Duan, Sining Bi, Khaing Nyein Chan Swe, Ziwei Xi, Yanan Gao, Yujie Zhou, Xiaomin Nie, Wei Liu · 2020 · Therapeutic Advances in Chronic Disease
91. Nephroprotective Effects of Tetramethylpyrazine Nitrone TBN in Diabetic Kidney Disease
    Mei Jing, Yun Cen, Fangfang Gao, Ting Wang, Jinxin Jiang, Qianqian Jian, Liangmiao Wu, Baojian Guo, Fangcheng Luo, Gaoxiao Zhang et al. · 2021 · Frontiers in Pharmacology
92. Time‐dependent risk of fracture in adults with type 2 diabetes receiving anti‐diabetic drug: A one‐stage network meta‐analysis
    Yanjiao Shen, Qingyang Shi, Xinyu Zou, Wentong Meng, Haoming Tian, Liang Du, Sheyu Li · 2024 · Diabetes/Metabolism Research and Reviews
93. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies
    Vasilis Tsimihodimos, Theodosios D. Filippatos, Moses Elisaf · 2016 · Expert Opinion on Drug Metabolism & Toxicology
94. Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: R eview of current strategies
    Guillermo E. Umpierrez, Timothy Silleck Bailey, Danielle Carcia, Charles F. Shaefer, Jay H. Shubrook, NEIL SKOLNIK · 2017 · Journal of Diabetes
95. Current molecular aspects in the development and treatment of diabetes
    Samuel Álvarez-Almazán, Jessica Georgina Filisola-Villaseñor, Diana Alemán-González-Duhart, Feliciano Tamay Cach, Jessica Elena Mendieta‐Wejebe · 2020 · Journal of Physiology and Biochemistry
96. Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT)
    Nicola Napoli, Raffaele Antonelli Incalzi, Giovanni Gennaro, Claudio Marcocci, Raffaele Marfella, Rocco Papalia, Francesco Purrello, Carmelinda Ruggiero, Umberto Tarantino, Flavia Tramontana et al. · 2021 · Nutrition Metabolism and Cardiovascular Diseases
97. Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes
    Pamela R. Kushner · 2016 · Women s Health
98. Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Jing Wang, Xin Li, Yang Li, Chen Lei · 2024 · BMC Endocrine Disorders
99. Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis
    Hee‐Ju Kim, Seo‐A Choi, Min‐Sun Gu, Seo‐Yeong Ko, Jae-Hee Kwon, Ja‐Young Han, Jae Hyun Kim, Myeong Gyu Kim · 2024 · Diabetes/Metabolism Research and Reviews
100. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
     Oren Steen, Ronald Goldenberg · 2017 · Canadian Journal of Diabetes